Yashar Mesbahi

Yashar Mesbahi

Auto-generated profile, based on publicly available information

Yashar Mesbahi

Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran; Institute of Biochemistry and Biophysics, University of Tehran, P.O. Box 13145-1384, Tehran, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YMYashar Mesbahi
Yashar Mesbahi
AZAli Zekri
Ali Zekri
SGSeyed H. Ghaffari
Seyed H. Ghaffari
PTParvaneh Sadat Tabatabaie
Parvaneh Sadat Tabatabaie
SAShahin Ahmadian
Shahin Ahmadian
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh

20 December 2017 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YMYashar Mesbahi
Yashar Mesbahi
AZAli Zekri
Ali Zekri
SAShahin Ahmadian
Shahin Ahmadian
KAKamran Alimoghaddam
Kamran Alimoghaddam
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
SGSeyed H. Ghaffari
Seyed H. Ghaffari

1 September 2017 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
PDF file
AZAli Zekri
Ali Zekri
YMYashar Mesbahi
Yashar Mesbahi
SGSamad Ghanizadeh-Vesali
Samad Ghanizadeh-Vesali
KAKamran Alimoghaddam
Kamran Alimoghaddam
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
SGSeyed H. Ghaffari
Seyed H. Ghaffari
Aurora-B kinase overexpression plays important roles in the malignant progression of prostate cancer (PCa). AZD1152-HQPA, as an inhibitor of Aurora-B, has recently emerged as a promising agent for cancer treatment. In this study, we aimed to investigate the effects of AZD1152-HQPA on reactive oxygen species (ROS) generation and mitochondrial function in PCa. We used AZD1152-HQPA (Barasertib), a highly potent and selective inhibitor of Aurora-B kinase. The effects of AZD1152-HQPA on cell viability, DNA content, cell morphology, and ROS production were studied in the androgen-independent PC-3 PCa cell line. Moreover, the mitochondrial copy number and the expression of genes involved in cell survival and cancer stem cell maintenance were investigated. We found that AZD1152-HQPA treatment induced defective cell survival, polyploidy, micronuclei formation, cell enlargement, and cell death by significant overexpression of p73, p21 and downregulation of cell cycle-regulatory genes in a drug concentration-dependent manner. Moreover, AZD1152 treatment led to an excessive ROS generation and an increase in the mitochondrial copy number not only in PC-3 but also in several other malignant cells. AZD1152 treatment also led to downregulation of genes involved in the maintenance of cancer stem cells. Our results showed a functional relationship between the aurora kinase inhibition, an increase in mitochondrial copy number, and ROS generation in therapeutic modalities of cancer. This study suggests that the excessive ROS generation may be a novel mechanism of cytotoxicity induced by the aurora kinase inhibitor, AZD1152-HQPA.

26 July 2018 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
AZAli Zekri
Ali Zekri
YMYashar Mesbahi
Yashar Mesbahi
EBElham Boustanipour
Elham Boustanipour
ZSZahra Sadr
Zahra Sadr
SGSeyed H. Ghaffari
Seyed H. Ghaffari